-
Innovation Ranking
NewInnovation Ranking – Nxt-ID Inc
LogicMark, LLC (LogicMark), formerly NXT-ID Inc, carries out the provision of a comprehensive platform of technology products and services. It provides security solutions to mobile devices. The company offers various products such as Wocket, a physical electronic smart wallet that holds information from credit cards, debit cards, loyalty cards, identification cards, and virtually any magnetic stripe. LogicMark provides Wi-Mag, a payment technology, SmartCard, a smartcard to make payments by magnetic stripe or through interacting with a terminal through EMC, NFC,...
-
Product Insights
NewNet Present Value Model: Ideaya Biosciences Inc’s IDE-161
Empower your strategies with our Net Present Value Model: Ideaya Biosciences Inc's IDE-161 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ID-93 in Pulmonary Tuberculosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ID-93 in Pulmonary Tuberculosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ID-93 in Pulmonary Tuberculosis Drug Details: ID-93 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ID-119031166 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ID-119031166 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ID-119031166 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: ID-119031166 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Prostate Cancer Drug Details: IDE-161 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Gastric Cancer Drug Details: IDE-161 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Colon Cancer Drug Details: IDE-161 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Endometrial Cancer Drug Details: IDE-161 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Solid Tumor Drug Details: IDE-161 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDE-161 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-161 in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-161 in Metastatic Ovarian Cancer Drug Details: IDE-161 is under development for...